Cellceutix nabs antibiotic in bankruptcy fire sale; Lawmaker urges BioMarin to act on compassionate-use petition;

@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech

@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce

@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride

@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce

> Cellceutix ($CTIX) has acquired virtually all of the assets from bankrupt Polymedix, including a mid-stage antibiotic. The buyout gives Cellceutix 9 molecules and Polymedix's old lab equipment. Story

> BioMotiv and New York University have formed Orca Pharmaceuticals, which aims to develop an oral drug for psoriasis. Story

> Rep. Jared Huffman (D-San Rafael, CA) has gotten involved in a drama involving a compassionate use request for one of BioMarin's ($BMRN) drugs. The lawmaker says BioMarin is considering putting a patient in one of its studies for the PARP inhibitor BMN 673 after officially rejecting her compassionate-use petition. Story

Medical Device News

@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev

@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce

@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Baxter finally closes $4B Gambro deal, eyes dialysis dominance. More

> CeQur's insulin pump draws $27M Series B. Article

> Sapheon nails down $19.8M for varicose vein treatment. Report

Pharma News

@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma

@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: GlaxoSmithKline selling two drinks brands to Japan's Suntory. Release | Follow @CarlyHFierce

> GlaxoSmithKline's China probe triggers U.S. bribery investigation. Article

> Boehringer targets sales reps in new round of French job cuts. Report

> Bayer's Xarelto faces stepped-up reports of side effects, deaths. Story

CRO News

> Novella shuffles execs as Quintiles deal pends. Item

> AMRI chief stepping down at year's end. News

> Patheon posts Banner quarter on 30% sales surge. Article

> Covance teams with Indiana U. for early trials. Story

> Capsugel snaps up Bend with eye on oral formulations. More

Biotech IT News

> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report

> Texas biotech software outfit trumpets open source tools. Item

> Genentech backs development of video game for kids with cancer. More

> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story

> Accelrys scoops up Bay Area software firm for $15.3M. Article

And Finally… Living Proof, the hair products company that relies on some of the science to come from the lab of MIT's prolific Robert Langer, has launched a new product. Release

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.